Plobsheim, France

Maurice W Gittos

This inventor holds 26 USPTO granted patents, plus 2 CIPO patents, primarily in Pharmaceutical Compositions. Top assignees: Merrell Dow Pharmaceuticals, Merrell Toraude Et Compagnie, National Research Development Corporation. Active years: 1979-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Maurice W Gittos. Retrieved from https://idiyas.com/inventor/maurice-w-gittos

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 96.2

 

Average Co-Inventor Count = 1.6

ph-index = 7

Forward Citations = 160(Granted Patents)


Location History:

  • Illkirch-Graffenstaden, FR (1984)
  • Plobsheim Illkirch-Graffenstaden FR (1984)
  • Strasbourg, FR (1979 - 1986)
  • Plobsheim, FR (1985 - 2007)

Company Filing History:


Years Active: 1979-2007

Loading Chart...
Loading Chart...
Areas of Expertise:
Dioxopiperidine
Migraine Treatment
Quinolizine Derivatives
Immune Response
Antihypertensive Agents
Piperidin-2,6-dione
Amide Analogs
Benzoisothiazol
Aromatic Compounds
Tropyl Benzoate
Hexahydro Compounds
26 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Maurice W. Gittos

Introduction: Maurice W. Gittos, based in Plobsheim, France, has made significant contributions to the field of pharmaceuticals, holding an impressive portfolio of 25 patents. His work primarily focuses on innovations that address various health issues, particularly stress-related disorders and chemotherapy-induced symptoms.

Latest Patents: Among his latest patents, Maurice W. Gittos has developed novel bisulphate salts, specifically targeting the treatment of stress-related affective disorders. The innovation involves bisulphate salts of certain 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-diones. These compounds have shown to be devoid of weight loss and hepatocyte changes in rats, thus enhancing the efficacy of clinical doses for conditions such as anxiety, depression, and migraine. His preferred compounds include 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione bisulphate, and 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione bisulphate.

Another notable patent involves the development of amide derivatives of certain 2,6-methano-2H-quinolizine-type compounds. This invention focuses on their potential therapeutic applications, including their role in antagonizing serotonin effects at the 5HT3 receptors, as well as their use in treating conditions such as nausea and vomiting induced by chemotherapy, migraine pain, and cognitive disorders.

Career Highlights: Maurice's career has been marked by innovative research and his dedication to improving pharmacological treatments. He has collaborated with leading pharmaceutical firms, including Merrell Dow Pharmaceuticals and Merrell Toraude Et Compagnie, where he applied his expertise in drug development and patenting.

Collaborations: Throughout his professional journey, Maurice W. Gittos has teamed up with notable colleagues, such as Marcel Hibert and John R. Fozard. Their collaboration has led to groundbreaking developments that push the boundaries of existing medical treatments.

Conclusion: Maurice W. Gittos exemplifies the impact of innovative thinking in the pharmaceutical industry. Through his extensive patent portfolio and collaborations with esteemed colleagues, he continues to make strides in developing effective solutions for complex health issues. His contributions not only enhance the understanding of pharmacological sciences but also pave the way for future advancements in medication and treatment therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…